Rani Therapeutics
RANI
31 hedge funds and large institutions have $12.8M invested in Rani Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
8.36% more ownership
Funds ownership: 11.82% → 20.18% (+8.4%)
8% more capital invested
Capital invested by funds: $11.8M → $12.8M (+$958K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 34 → 31 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
50% less call options, than puts
Call options by funds: $6K | Put options by funds: $12K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.38M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$387K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$202K |
| 4 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$71.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$80.7K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$45K |
| 3 |
VF
Virtu Financial
New York
|
-$39K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$36.4K |
| 5 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$34.3K |
RANI Hedge Fund Activity: Q3 2024 in Review
31 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q3 2024, worth a combined $12.8M — up 8.1% from $11.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RANI and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $7.38M. The largest seller was Marshall Wace, exiting entirely with an estimated $80.7K sold.
- 31 institutional investors held Rani Therapeutics (RANI) as of Q3 2024, down from 34 in Q2 2024.
- Funds reported $12.8M of Rani Therapeutics stock for Q3 2024, up 8.1% quarter-over-quarter.
- 3 funds opened new Rani Therapeutics positions in Q3 2024 and 6 closed out, a net change of -3 holders.
- The largest Rani Therapeutics buyer in Q3 2024 was Armistice Capital, an estimated $7.38M added.
- The largest Rani Therapeutics seller in Q3 2024 was Marshall Wace, an estimated $80.7K sold.
Based on aggregated 13F filings for Q3 2024.